Bryan Dechairo

Mr. Bryan Dechairo is the chief executive officer of Sherlock Biosciences, and also serves on its board of directors. He has more than 25 years of experience developing and commercializing revenue generating clinical innovations that improve patient lives. Prior to joining Sherlock Biosciences, Mr. Dechairo served as executive vice president of clinical development at Myriad Genetics, where he oversaw the development portfolio, delivering business-critical evidentiary data for value-based reimbursement and market acceptance of commercial and novel diagnostic products across six business units globally. Before joining Myriad Genetics, he was chief medical officer, chief scientific officer and senior vice president of research and development at Assurex Health, which was acquired by Myriad in 2016. During his extensive career, Mr. Dechairo held roles of increasing responsibility at Medco, Pfizer, Oxagen, Sequana and Roche, where he established a proven track record of funding and scaling businesses from venture backed start-ups to profitable fortune 50 public companies. He also authored more than 50 academic and research-based publications, and earned a Ph.D. in Common Complex Human Genetics from the Institute of Child Health at University College London and a B.A. in Integrative Biology from the University of California, Berkeley.